Ligand Enters into OmniAb Platform License with xCella

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with its OmniAb Platform License with xCella Biosciences for human antibody discovery using transgenic rodents. Read the press release.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. xCellla is a protein engineering and drug discovery company.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.